Kiora reports Q3 net income of $27K; cash runway into late 2027; two Phase 2 trials enrolling

KIORA PHARMACEUTICALS INC

2025-Q3 EPS reported -$1.04

Cash, equivalents and investments $19.4M; collaboration receivables $1.2M; tax receivables $1.5M.
R&D expense $2.7M (net of $1.7M Théa reimbursement) vs $2.1M in Q3 2024.
Q3 2025 net income $27K vs net loss of $3.4M in Q3 2024, driven by tax impacts and noncash gains.
Both Phase 2 trials — KLARITY (KIO-104 for retinal inflammation) and ABACUS-2 (KIO-301 for retinitis pigmentosa) — continue recruitment and dosing.
Received $1.2M in reimbursed R&D from Théa in Q3; billed an additional $1.5M in the quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.